Pharma Mar SA – Strategy, SWOT and Corporate Finance Report
- Pages: 50
- Published: August 2019
- Report Code: MLPH140326FSA
Pharma Mar SA – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company
Key Highlights
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar’s developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; Zepsyre (lurbinectedin) for small cell lung cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.
Scope
Detailed information on Pharma Mar SA required for business and competitor intelligence needs
A study of the major internal and external factors affecting Pharma Mar SA in the form of a SWOT analysis
An in-depth view of the business model of Pharma Mar SA including a breakdown and examination of key business segments
News about Pharma Mar SA, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Pharma Mar SA and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess Pharma Mar SA as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Pharma Mar SAs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
Ability Pharmaceuticals SL
Ariad Pharmaceuticals (Spain) SL
GP Pharm SA
Traslational Cancer Drugs Pharma SL
CTI BioPharma Corp
Oryzon Genomics SA
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple report purchases.